What Happened?
Shares of healthcare tech company GoodRx (NASDAQ: GDRX) jumped 7% in the afternoon session after the company reported first-quarter 2026 financial results that surpassed revenue expectations and raised its full-year guidance.
For the quarter, GoodRx posted revenue of $194 million, beating Wall Street's estimates of $184.6 million, while its adjusted earnings per share of $0.07 was in line with expectations. Bolstered by the performance, the company lifted its full-year revenue forecast to a midpoint of $775 million. Despite the revenue beat and raised guidance, total revenue still fell 4.4% year-over-year, and its free cash flow was negative for the quarter.
Is now the time to buy GoodRx? Access our full analysis report here, it’s free.
What Is The Market Telling Us
GoodRx’s shares are extremely volatile and have had 36 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 6 days ago when the stock gained 9.5% on the news that it announced it would provide access to Novo Nordisk's oral semaglutide medication, known as the Ozempic pill, for eligible self-pay patients with type 2 diabetes.
The prescription savings platform detailed that the popular diabetes treatment would be available starting at $149 per month for a 1.5mg dose through its nationwide pharmacy network, with higher dosages of 4mg and 9mg priced at $199 and $299 per month, respectively. This move adds an oral option to the widely used Ozempic treatment, potentially broadening its accessibility for patients who prefer pills over injections. By offering competitive self-pay pricing for a high-demand medication, GoodRx is tapping into the growing market for this class of drugs.
GoodRx is up 1.6% since the beginning of the year, but at $2.80 per share, it is still trading 45.4% below its 52-week high of $5.12 from August 2025. Despite the year-to-date gain, investors who bought $1,000 worth of GoodRx’s shares 5 years ago would now be looking at only $80.45.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
